Clinical pathways and outcomes of andexanet alfa administration for reversal of critical bleeding in patients on oral direct factor Xa inhibitors

Clinical pathways and outcomes of andexanet alfa administration for reversal of critical bleeding in patients on oral direct factor Xa inhibitors

Background: Andexanet is FDA-approved for reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes. Methods: We retrospectively studied patients at a 23-hospital system who received andexanet from November 20...

Full description

Bibliographic Details
Main Authors: Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniela Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos
Format: Article
Language:English
Published: Georg Thieme Verlag KG
Series:TH Open
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/a-2306-0804

Internet

http://www.thieme-connect.de/DOI/DOI?10.1055/a-2306-0804

Similar Items